Strengthening EU Health Competitiveness: MedTech Europe’s Call for Strategic Reforms

By João L. Carapinha

December 3, 2024

MedTech Europe recently wrote an open letter to EU Member States’ Representatives on EU Health Competitiveness. The letter discusses the strategic importance of medical technology, and it focuses on developing the EU’s healthcare sector and maintaining competitiveness. Here’s a detailed analysis of these points:

Strategic Investments in EU Healthcare Competitiveness

MedTech Europe calls for investment in efficient healthcare systems. They emphasize the role of digital health and medical technologies which matches the European Health Union’s goals. The EU aims to improve health systems across member states. The Commission highlighted that digital health as crucial and that these tools can help address challenges like cancer care and prevention.

Regulatory Framework Reform

The letter calls for a structural reform of the regulatory framework, specifically the implementation of Regulations (EU) 2017/745 and 2017/746, to foster timely and safe innovation launches. This is echoed in prior open letters by MedTech Europe that highlights the urgent need for action on medical technology regulations (IVDR and MDR) to ensure device availability and competitiveness. The industry proposes immediate ‘bridging measures’ to reduce certification times and costs and to improve the efficiency of assessing changes to medical technologies.

Policy Synchronisation

MedTech Europe advocates for policy synchronisation to align regulatory requirements across different policy domains, thereby reducing legal uncertainty and the regulatory burden. This approach supports the European Health Union’s goal of streamlining processes and improving coordination. For instance, the European Commission’s proposed reform of the pharmaceutical legislation aims to cut red tape and expedite drug evaluation procedures, which is part of a broader effort to synchronize and streamline regulatory processes.

Value-Based Procurement

The letter promotes procurement practices focused on value and complements a joint decarbonisation and competitiveness approach. This is consistent with investing in governance and public health infrastructure, as emphasized by the European Public Health Association (EUPHA) and the European Health Management Association (EHMA). They stress the importance of direct financial incentives to support actions that boost workability, emphasize prevention, and allow for additional capacity in health systems.

Innovation and Competitiveness

MedTech Europe stresses the need to strengthen Europe’s global leadership in healthcare innovation. This is a recurring theme across various sources discussing the medical technology sector’s role. The European Commission’s Pharmaceutical Strategy for Europe and the proposed reform of pharmaceutical rules aim to support health innovation. Nonetheless, there are concerns from stakeholders, such as the European Federation of Pharmaceutical Industries and Associations (EFPIA), that certain reforms could undermine the EU’s competitiveness in health innovation.

Patient Empowerment and Health Literacy

The MedTech Europe letter doesn’t directly discuss patient empowerment. However, this remains crucial for the European Health Union. EUPHA and EHMA stress two key points: health literacy and patient empowerment. They believe patients should be active partners in making decisions about their care.

Addressing Social Disparities

The European Health Union aims to address social disparities in healthcare. Building fairer health systems is a core goal. EUPHA and EHMA advocate for better health promotion. They focus on fixing disparities that grew worse during COVID-19.

In summary, MedTech Europe’s letter outlines vital areas for EU healthcare. It covers investments, reforms, and policy changes. The letter discusses value-based procurement and innovation support. It also addresses social gaps in healthcare. Multiple sources back these recommendations. These include European Commission reports and joint statements. EUPHA and EHMA also support this comprehensive approach. Together, they aim to strengthen EU medical technology.

 

Reference url

Recent Posts

suzetrigine pain management
      

Journavx for Pain Management: Toward Affordability and Access

💊 The jury is out on the pricing for Journavx®

Delve into our review of the recent ICER 2025 report on suzetrigine (Journavx®) to learn about the anticipated value relative to its clinical efficacy, safety profile and potential cost savings in tackling acute pain while addressing the opioid crisis.

Explore how suzetrigine paves the way for a safer, more effective approach to pain management and its implications on healthcare economics.

#SyenzaNews #HealthEconomics #HealthcareInnovation #Journavx

defunding scientific research
      

Defunding Scientific Research: Implications and Misconceptions in Gawande’s Analysis of Harvard Funding Cuts

🚨 What happens when scientific research funding is threatened?

In his thought-provoking article, Atul Gawande highlights the dire implications of proposed federal funding cuts to elite institutions like Harvard. He argues that such actions could devastate not just innovation, but also patient care and public health across the nation.

Explore the complexities of research funding and the potential ripple effects on America’s scientific landscape. Don’t miss out on these critical insights!

#SyenzaNews #HealthcareInnovation #HealthEconomics #MarketAccess

perioperative immunotherapy bladder cancer
       

FDA Approves Perioperative Immunotherapy for Bladder Cancer: A Breakthrough in MIBC Treatment

🚀 Are we witnessing a new era in bladder cancer treatment?

The FDA’s recent approval of durvalumab as the first perioperative immunotherapy for muscle-invasive bladder cancer (MIBC) could revolutionize outcomes for patients facing this formidable diagnosis. With significant improvements in event-free survival and overall survival over standard chemotherapy, this groundbreaking treatment offers new hope 🎉.

Curious about how this could shape the future of cancer care? Dive into the full article to uncover the potential impacts on clinical practice and health economics.

#SyenzaNews #oncology #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.